8-Jun-2017: CCMB develops a novel drug-delivery system for treating keratitis eye infection

Scientists at the Hyderabad-based CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) have developed a novel way to treat fungal keratitis.

Treating keratitis infection is currently a challenge because it is difficult to maintain a therapeutic dose at the corneal surface for long periods as blinking and tear formation washes off the drug. To address this challenge, scientists have developed protein-based nanoparticles that encapsulate the drug.

Certain antibodies get attached to the outer surface of the nanoparticles, thus anchoring the nanoparticles to the corneal surface. The infected cornea expresses a set of receptors (TLR4) when infection sets in. Scientists have used antibodies to these receptors to anchor the nanoparticles to the cornea.

If the infection is severe, more receptors are expressed on the cornea and more nanoparticles get bound to the receptors. Since they are bound, the residence time in the eye is long; neither blinking nor tear formation washes off the nanoparticles. The enzymes secreted by fungi breaks down the gelatine protein of nanoparticles that encapsulates the drug, thus releasing the drug. Like in the case of the receptors, more enzyme is secreted when infection is severe leading to more drug being released from the nanoparticles. The gelatine protein acts as an alternative nutrient for the fungi. The fungi also degrade the gelatine-based nanoparticle to derive nutrients thus minimising the damage to the corneal tissue. In the process it releases the drug. In a sense, the fungi are committing suicide by consuming the gelatine protein.